Newswise WASHINGTON (Jan. 3, 2012) Research out of the George Washington University (GW), published in the journal Proceedings of the National Academy of Sciences (PNAS), reveals another piece of the puzzle in a genetic developmental disorder that causes behavioral diseases such as autism. Anthony-Samuel LaMantia, Ph.D., professor of pharmacology and physiology at the GW School of Medicine and Health Sciences (SMHS) and director of the GW Institute for Neuroscience, along with post-doctoral fellow Daniel Meechan, Ph.D. and Thomas Maynard, Ph.D., associate research professor of pharmacology and physiology at GW SMHS, authored the study titled Cxcr4 regulation of interneuron migration is disrupted in 22q11.2 deletion syndrome. For the past nine years, LaMantia and his colleagues have been investigating how behavioral disorders such as autism, attention deficit hyperactivity disorder (ADHD), and schizophrenia arise during early brain development. His work published in PNAS focuses specifically on the effects diminished 22q11.2 gene dosage has on cortical circuit development. This research shows for the first time that genetic lesions known to be associated with autism and other behavioral diseases disrupt cellular and molecular mechanisms that ensure normal development of a key type of cortical neuron: the interneuron. LaMantia and his colleagues had found previously that … Continue reading →

Public release date: 3-Jan-2013 [ | E-mail | Share ] Contact: Lisa Anderson lisama2@gwu.edu 202-994-3121 George Washington University WASHINGTON (Jan. 3, 2012) Research out of the George Washington University (GW), published in the journal Proceedings of the National Academy of Sciences (PNAS), reveals another piece of the puzzle in a genetic developmental disorder that causes behavioral diseases such as autism. Anthony-Samuel LaMantia, Ph.D., professor of pharmacology and physiology at the GW School of Medicine and Health Sciences (SMHS) and director of the GW Institute for Neuroscience, along with post-doctoral fellow Daniel Meechan, Ph.D. and Thomas Maynard, Ph.D., associate research professor of pharmacology and physiology at GW SMHS, authored the study titled "Cxcr4 regulation of interneuron migration is disrupted in 22q11.2 deletion syndrome." For the past nine years, LaMantia and his colleagues have been investigating how behavioral disorders such as autism, attention deficit hyperactivity disorder (ADHD), and schizophrenia arise during early brain development. His work published in PNAS focuses specifically on the effects diminished 22q11.2 gene dosage has on cortical circuit development. This research shows for the first time that genetic lesions known to be associated with autism and other behavioral diseases disrupt cellular and molecular mechanisms that ensure normal development … Continue reading →

Emily Schaller suffers from cystic fibrosis. New treatments that target the genetic basis of her disease allow her to live an active, healthy life. The promise of genetic medicine is beginning to be fulfilled, but it's been a long, hard slog. Take the story of Kalydeco. It's designed to treat people with a lung disease called cystic fibrosis. While not quite a cure, the drug is extremely effective for some CF patients. But the success of Kalydeco has been more than two decades in the making. A good starting point for the story is Aug. 24, 1989. That's the day scientists from the U.S. and Canada announced the discovery of the gene associated with the disease. It was the early days of gene hunting, and the CF gene was a big prize. CF is the most common genetic disease in Caucasians. When people inherit a damaged form of the CF gene, a critical protein inside cells doesn't work properly. As a result, sticky mucus builds up in a patient's lungs, causing infections and making it hard to breathe. The announcement was supposed to be made in conjunction with three papers in the Sept. 8 issue of Science, but a reporter … Continue reading →

ABC Suzanne Somers Tries New Stem Cell Treatment By: Joel Aronowitz … Continue reading →

WISE Stem Cell Testimonial Patient undergoes stem cell treatment for diabetes and tells about his experience during the treatment in Panama, as well as the results he has experienced. To learn more about stem treatments for a multitude of ailments including diabetes, cosmetic rejuvenation, Parkinson's disease, Multiple Sclerosis, rheumatic diseases (including osteoporosis, rheumatoid arthritis, and others) and many more, please contact the World Institute of Surgical Excellence "WISE" at info@wisemds.com. By: WISEMDS … Continue reading →